Loading DRMAW…
Loading financial statements…
Import this data to Google Sheets with:
=jivedata("DRMA","financials")Full statements spill as a table. For one cell: =jivedata("DRMA","Revenue") or =jivedata("DRMA","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.
DRMA • CIK 0001853816
| (in thousands, except per share data) | FY 2023 | FY 2024 | FY 2025 | TTM |
|---|---|---|---|---|
| Research and Development Expense | $4,069.766 | $8,203.691 | $2,929.983 | $1,266.201 |
| Selling, General and Administrative Expense | — | — | $4,843.615 | $8,472.769 |
| Operating Income (Loss) | $-8,041.906 | $-12,513.242 | $-7,773.598 | $-9,698.841 |
| Operating Expenses | $8,041.906 | $12,513.242 | $7,773.598 | $9,738.97 |
| Net Income (Loss) Attributable to Parent | $-7,794.69 | $-12,287.461 | $-7,558.557 | $-9,498.057 |
| Weighted Average Number of Shares Outstanding, Basic | — | — | 926,192 | 4,406,326 |
| Weighted Average Number of Shares Outstanding, Diluted | — | 1,529,772 | 926,192 | 4,406,326 |
| Investment Income, Interest | — | — | $215.041 | $200.784 |
| General and Administrative Expense | $3,972.14 | $4,309.551 | — | $4,045.651 |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 8,460,771 | 5,120,796 | 5,445,094 | 14,408,420 |
| (in thousands, except per share data) | FY 2023 | FY 2024 | FY 2025 | TTM |
|---|---|---|---|---|
| Cash and Cash Equivalents, at Carrying Value | — | — | $7,521.978 | $4,822.357 |
| Prepaid Expense and Other Assets, Current | $540.499 | $372.318 | $341.848 | $583.314 |
| Assets | $7,978.634 | $3,533.888 | $7,863.826 | $6,635.491 |
| Accounts Payable, Current | $866.028 | $808.011 | $460.811 | $1,619.972 |
| Accrued Liabilities and Other Liabilities | $757.588 | $1,164.783 | $1,179.635 | $1,109.593 |
| Liabilities | $1,623.616 | $1,972.794 | $1,640.446 | $2,729.565 |
| Common Stock, Value, Issued | $0.393 | $0.252 | $0.266 | $0.493 |
| Additional Paid in Capital | $59,742.503 | $67,236.181 | $79,457.01 | $84,775.498 |
| Retained Earnings (Accumulated Deficit) | $-53,387.878 | $-65,675.339 | $-73,233.896 | $-80,870.065 |
| Stockholders' Equity Attributable to Parent | $6,355.018 | $1,561.094 | $6,223.38 | $3,905.926 |
| Other Accrued Liabilities, Current | — | — | $200.182 | $37.499 |
| Common Stock, Shares Authorized | 250,000,000 | 250,000,000 | 250,000,000 | 250,000,000 |
| Common Stock, Shares, Issued | 3,930,840 | 2,517,768 | 2,660,110 | 4,930,207 |
| Prepaid Insurance | — | — | $255.272 | $300.124 |
| Other Prepaid Expense, Current | — | — | $53.835 | $86.967 |
| Employee-related Liabilities, Current | — | — | $979.453 | $392.17 |
| (in thousands, except per share data) | FY 2023 | FY 2024 | FY 2025 | TTM |
|---|---|---|---|---|
| Net Income (Loss) Attributable to Parent | $-7,794.69 | $-12,287.461 | $-7,558.557 | $-9,498.057 |
| Net Cash Provided by (Used in) Operating Activities | $-6,408.931 | $-11,162.948 | $-7,757.559 | $-8,880.22 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | $4,360.408 | $358.23 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $7,438.135 | $3,161.57 | $7,521.978 | $4,747.992 |
| Share-based Payment Arrangement, Noncash Expense | $522.082 | $657.649 | $143.732 | $156.706 |
| Proceeds from Issuance of Common Stock | $7,605.625 | $6,886.102 | $12,167.852 | $7,499.398 |
| Payments of Stock Issuance Costs | — | — | $50.495 | $91.352 |
| Proceeds from Warrant Exercises | $0.187 | $1.109 | $0.977 | $0.977 |
| Net Cash Provided by (Used in) Financing Activities | $7,605.772 | $6,886.383 | $12,117.967 | $9,402.097 |
| Income Taxes Paid | $0.95 | $0.95 | $0.95 | $0.95 |
| Increase (Decrease) in Prepaid Expense and Other Assets | $-162.695 | $-168.181 | $-30.47 | $177.949 |
| Increase (Decrease) in Accounts Payable | $369.326 | $-108.512 | $-388.056 | $1,091.16 |
| Increase (Decrease) in Accrued Liabilities | — | — | $14.852 | $405.925 |